This is a Ireland news story, published by Investigate Europe, that relates primarily to Miriam Staunton news.
For more Ireland news, you can click here:
more Ireland newsFor more Miriam Staunton news, you can click here:
more Miriam Staunton newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investigate Europe, you can click here:
more news from Investigate EuropeOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
cancer drug. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest melanoma patients news, breakthrough drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Miriam StauntonInvestigate Europe
•85% Informative
Irish woman Miriam Staunton was unable at first to access the cancer drug she needed because it was not available in Ireland .
Opdivo combined with Yervoy , breakthrough drugs known as immunotherapy, was restricted to the most severe forms of cancer in Ireland due to their high costs.
In July 2018 , the European Medicines Agency ( EMA ) opened the therapy to stage three melanoma patients.
France immediately reimbursed it, but Ireland did not.
15 of the world’s biggest drugmakers operate more than 1,300 subsidiaries in tax-friendly jurisdictions.
The arrangement resembles an infamous tax avoidance loophole that Ireland vowed to close.
Ireland made changes to its corporate tax residence rules in Finance Act 2014 that are specifically designed to prevent such structures as the so-called ' Double Irish' .
In the Netherlands , Pfizer booked three-quarters of its $100 billion global revenues with a Dutch holding at the helm of a myriad of subsidiaries.
Pharmaceutical executives often cite expensive R&D costs as a major reason why medicine prices are high.
Data compiled by Investigate Europe shows that the industry reaps more profits from sales of existing drugs than it invests in developing new ones.
VR Score
87
Informative language
89
Neutral language
19
Article tone
semi-formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
15
Source diversity
14
Affiliate links
no affiliate links